Nephrocare Health Services IPO: Nephrocare Health Services, the largest company in Asia, providing dialysis service, has submitted draft papers with the Capital Market Regulator SEBI for its IPO. Sources have told Moneycontrol that about Rs 2,000 crore can be raised from the IPO. The company operates under the Nephroplus brand. New equity shares worth Rs 353.4 crore will be issued in its IPO. Also, the offer of 1.28 crore shares will be offered for SAIL (OSS) from promoters and existing shareholders.
Promoter Vikram Vuppala, BVP Trust, Investcorp, Healthcare Parent, Edorus Investment Holdings, as well as International Finance Corporation and 360 One Special Opportunities Funds etc. will be kept for sale.
70.68 crore can be raised in pre-IPO round
Nephroplus can raise Rs 70.68 crore in the pre-IPO round. If this happens, the size of the issue of new shares in the IPO will decrease. Promoters hold 78.90 percent stake on the fully dialiced basis in the company. The remaining 21.1 percent holds with public shareholders. Promoters of Nephrocare Health Services include Vikram Vuppala, BVP (Baseer Venture Partners) Trust, Adorus Investment Holdings, Healthcare Parent and Invest Corp. Quadria is part of Capital India Fund, Pankaja Gatuku, Manvi Family Trust and Viraj Family Trust, Promoter Group.
Vikram Vuppala and Kamal D. Shah launched nephroplas in 2010. Telangana -based nephrocare health services provides all types of dialysis care, from diagnosis to treatment and hemodialysis, home and mobile dialysis. It is Asia’s largest dialysis service provider. It has a network of 490 Clinics, including 43 international clinics in the Philippines, Uzbekistan and Nepal.
How to use Nephroplus IPO money
The company will spend Rs 129.1 crore out of the earnings from releasing new shares in its IPO to open a new dialysis clinic in India. Apart from this, Rs 136 crore will be used for repayment of debt and the remaining money will be used for general corporate purposes. Nephrocare Health Services said in its DRHP (Draft Red Herring Prospectus) that by May 2025, it had a borrowing of Rs 280.6 crore on a consolidated basis.
Company’s financial position
Nephroplus had a profit of Rs 67.1 crore in FY 2025. This is 91 percent higher than the profit of a year ago. Revenue was recorded at Rs 755.8 crore, which is 33.5 percent higher than the financial year 2024. ICICI Securities, Ambit, IIFL Capital Services and Nomura Financial Advisory and Securities (India), Merchant Bankers are for Nephrocare Health Services IPO.